Table 4.
Joint effects analysis of expression of p53, p21, nm23 and VEGF with 2-year, 5-year and overall survival.
| Variable | Number (n=419) |
2-year OS P-value |
2-year OS HR(95% CI) |
5-year OS P-value |
5-year OS HR(95% CI) |
Overall survival P-value |
Overall survival HR(95% CI) |
|---|---|---|---|---|---|---|---|
| p53/p21 | |||||||
| 0 | 176 | 0.061 | 1.000 | 0.036 | 1.000 | 0.187 | 1.000 |
| 1 | 210 | 0.138 | 0.743(0.502-1.100) | 0.027 | 0.697(0.506-0.960) | 0.089 | 0.771(0.571-1.041) |
| 2 | 33 | 0.200 | 1.500(0.807-2.788) | 0.557 | 1.171(0.692-1.981) | 0.898 | 1.034(0.619-1.726) |
| p53/nm23 | |||||||
| 0 | 32 | 0.607 | 1.000 | 0.493 | 1.000 | 0.364 | 1.000 |
| 1 | 234 | 0.529 | 1.289(0.585-2.837) | 0.750 | 1.095(0.627-1.910) | 0.543 | 1.174(0.700-1.970) |
| 2 | 153 | 0.858 | 1.077(0.476-2.438) | 0.708 | 0.895(0.500-1.600) | 0.819 | 0.939(0.547-1.612) |
| p53/VEGF | |||||||
| 0 | 202 | 0.125 | 1.000 | 0.334 | 1.000 | 0.229 | 1.000 |
| 1 | 171 | 0.994 | 0.998(0.680-1.465) | 0.291 | 0.840(0.608-1.161) | 0.261 | 0.839(0.618-1.139) |
| 2 | 46 | 0.047 | 0.450(0.205-0.988) | 0.204 | 0.713(0.423-1.201) | 0.122 | 0.675(0.410-1.111) |
| p21/nm23 | |||||||
| 0 | 31 | 0.317 | 1.000 | 0.237 | 1.000 | 0.468 | 1.000 |
| 1 | 288 | 0.192 | 0.639(0.326-1.252) | 0.094 | 0.641(0.380-1.079) | 0.266 | 0.748(0.449-1.247) |
| 2 | 100 | 0.536 | 0.798(0.390-1.631) | 0.247 | 0.717(0.409-1.259) | 0.553 | 0.847(0.490-1.464) |
| p21/VEGF | |||||||
| 0 | 225 | 0.421 | 1.000 | 0.189 | 1.000 | 0.319 | 1.000 |
| 1 | 177 | 0.263 | 0.802(0.545-1.18) | 0.818 | 0.964(0.705-1.318) | 0.800 | 0.962(0.713-1.297) |
| 2 | 17 | 0.385 | 0.635(0.228-1.771) | 0.068 | 0.389(0.141-1.073) | 0.131 | 0.578(0.284-1.178) |
| nm23/VEGF | |||||||
| 0 | 32 | 0.141 | 1.000 | 0.321 | 1.000 | 0.289 | 1.000 |
| 1 | 299 | 0.701 | 0.872(0.435-1.751) | 0.687 | 0.894(0.518-1.542) | 0.868 | 1.046(0.617-1.773) |
| 2 | 88 | 0.133 | 0.538(0.240-1.208) | 0.222 | 0.675(0.359-1.269) | 0.411 | 0.778(0.427-1.416) |
| p53/p21/nm23 | |||||||
| 0 | 23 | 0.201 | 1.000 | 0.104 | 1.000 | 0.388 | 1.000 |
| 1 | 170 | 0.690 | 0.849(0.379-1.899) | 0.462 | 0.797(0.436-1.458) | 0.817 | 0.932(0.516-1.685) |
| 2 | 196 | 0.335 | 0.674(0.302-1.504) | 0.097 | 0.600(0.329-1.096) | 0.329 | 0.747(0.416-1.342) |
| 3 | 30 | 0.570 | 1.313(0.513-3.362) | 0.957 | 1.021(0.49-2.126) | 0.912 | 1.041(0.507-2.138) |
| p53/p21/VEGF | |||||||
| 0 | 135 | 0.543 | 1.000 | 0.303 | 1.000 | 0.302 | 1.000 |
| 1 | 198 | 0.413 | 0.840(0.553-1.276) | 0.081 | 0.735(0.519-1.039) | 0.122 | 0.770(0.553-1.073) |
| 2 | 81 | 0.158 | 0.667(0.381-1.17) | 0.218 | 0.763(0.497-1.173) | 0.257 | 0.791(0.527-1.187) |
| 3 | 5 | 0.933 | 1.064(0.250-4.529) | 0.376 | 0.523(0.125-2.195) | 0.184 | 0.440(0.131-1.479) |
| p21/nm23/VEGF | |||||||
| 0 | 22 | 0.156 | 1.000 | 0.028 | 1.000 | 0.067 | 1.000 |
| 1 | 222 | 0.043 | 0.477(0.233-0.979) | 0.024 | 0.503(0.277-0.913) | 0.071 | 0.581(0.322-1.048) |
| 2 | 160 | 0.058 | 0.498(0.242-1.024) | 0.085 | 0.591(0.325-1.075) | 0.223 | 0.691(0.381-1.253) |
| 3 | 15 | 0.061 | 0.282(0.075-1.061) | 0.008 | 0.179(0.050-0.638) | 0.016 | 0.311(0.120-0.804) |
| p53/nm23/VEGF | |||||||
| 0 | 25 | 0.198 | 1.000 | 0.448 | 1.000 | 0.300 | 1.000 |
| 1 | 191 | 0.792 | 1.121(0.479-2.624) | 0.872 | 1.052(0.569-1.944) | 0.556 | 1.194(0.662-2.153) |
| 2 | 161 | 0.846 | 1.089(0.460-2.578) | 0.668 | 0.871(0.463-1.638) | 0.941 | 0.977(0.535-1.786) |
| 3 | 42 | 0.167 | 0.447(0.143-1.400) | 0.375 | 0.705(0.325-1.527) | 0.459 | 0.757(0.362-1.582) |
| p53/p21/nm23/VEGF | |||||||
| 0 | 17 | 0.734 | 1.000 | 0.283 | 1.000 | 0.390 | 1.000 |
| 1 | 137 | 0.378 | 0.675(0.282-1.618) | 0.347 | 0.721(0.364-1.426) | 0.593 | 0.831(0.421-1.638) |
| 2 | 185 | 0.261 | 0.613(0.261-1.439) | 0.092 | 0.562(0.287-1.099) | 0.261 | 0.683(0.352-1.328) |
| 3 | 76 | 0.205 | 0.549(0.217-1.388) | 0.240 | 0.650(0.316-1.335) | 0.450 | 0.759(0.372-1.551) |
| 4 | 4 | 0.407 | 0.405(0.048-3.428) | 0.136 | 0.207(0.026-1.645) | 0.092 | 0.262(0.055-1.245) |
Notes: a Adjusted for drinking status, BCLC stages, PVTT, radical hepatic resection and adjuvant antiviral treatment. OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not available.